Merck and Pfizer among top picks as Goldman Sachs projects 2021 biopharma M&A activity | Seeking Alpha
- With an estimated ~$530B war chest in total, large biopharma companies will continue to drive M&A activity in 2021, the analysts at Goldman Sachs predicted in a new analysis of the sector.
- Noting a ~110% YoY rise in deal volumes in February including ~221% YoY growth in U.S. mid-cap deals, the analysts expect that given a favorable environment, the M&A activity could follow the trend set in 2H 2020.
- Merck, Pfizer, Bristol-Myers Squibb, Sanofi, and GlaxoSmithKline are likely to be at the forefront of M&A activity, the analysts argue noting the losses of exclusivity hurting the valuations of potential acquirers.
- Arguing that therapeutic areas remain a priority for many acquirers, the analysts cite oncology and immunology as areas where many companies are exposed to, with a rising interest in neurology and compelling valuation of “late-stage gene therapy” stocks after recent underperformance.
- Forums
- ASX - By Stock
- RAC
- Oncology - Pharma Deals News
Oncology - Pharma Deals News, page-147
-
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.49 |
Change
0.045(3.13%) |
Mkt cap ! $254.7M |
Open | High | Low | Value | Volume |
$1.46 | $1.50 | $1.46 | $69.61K | 47.07K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5278 | $1.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.51 | 734 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5278 | 1.485 |
1 | 1171 | 1.470 |
2 | 2150 | 1.465 |
2 | 1637 | 1.460 |
3 | 3848 | 1.455 |
Price($) | Vol. | No. |
---|---|---|
1.505 | 734 | 2 |
1.510 | 4430 | 1 |
1.515 | 5711 | 1 |
1.520 | 1800 | 1 |
1.530 | 10000 | 1 |
Last trade - 10.57am 12/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |